Transcript of Earnings Conference Call - Q2 and H1 FY27

November 5, 2026 Listing Department, Listing Department, National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Dalal Street, Mumbai - 400 051 Mumbai - 400 001 NSE Symbol: ARTEMISMED Scrip Code: 542919 Sub: Transcript of Earnings Conference Call - Q2 and H1 FY27 Dear Sir/Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed transcript of Earnings Conference Call held on November 2, 2026, to discuss the operational and financial performance of the Company for Q2 and H1 FY27. The said transcript is also available on the website of the Company at www.artemishospitals.com/investors. This is for your information and records. Thanking you, Yours faithfully, For Artemis Medicare Services Limited Poonam Makkar Company Secretary and Compliance Officer Encl.: As above “Artemis Medicare Services Limited Q2 & H1 FY27 Earnings Conference Call” November 02, 2026 MANAGEMENT: DR. DEVLINA CHAKRAVARTY – MANAGING DIRECTOR MR. SANJIV KOTHARI – CHIEF FINANCIAL OFFICER MR. RUDRA NARAYAN ACHARJEE – HEAD, INVESTOR RELATION, M&A AND ORG. GROWTH MODERATOR: MR. HIMANSHU BINANI – ANAND RATHI SHARES AND STOCK BROKING LIMITED Page 1 of 13 Artemis Medicare Services Limited November 02, 2026 Moderator: Ladies and gentlemen, good day and welcome to the Artemis Medicare Q2 and H1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Himanshu Binani from Anand Rathi Shares and Stock Brokers. Thank you, and over to you, sir. Himanshu Binani: Thank you, Steev. Good day everyone and welcome to the second quarter and first half FY27 earnings conference call of Artemis Medicare hosted by Anand Rathi Shares and Stock Broking Limited. From the management, we have Dr. Devlina Chakravarty, Managing Director, Mr. Sanjiv Kothari, CFO of the company, and Mr. Rudra Narayan, Head, Investor Relation, M&A And Org. Growth. I would like to thank the management for giving us this opportunity to host this call. We will begin the call with a brief opening remark from the management, post which we will have the session open for Q&A. Without further ado, I would like to hand over the call to Dr. Devlina. Thank you, and over to you, ma'am. Devlina Chakravarty: Thank you, Himanshu. Good morning, friends. I would like to begin with a brief view of the healthcare sector. The Indian hospital industry continues to expand, supported by growing patient demand, higher realization and the addition of new beds. However, India's hospital infrastructure remains below several international benchmarks, creating scope for further investment in advanced healthcare services. As treatments become more specialized, patients increasingly look for hospitals that can bring together the right medical teams, infrastructure and coordinated care for complex conditions. In- line with this, our strategy remains focused on strengthening our clinical capabilities, expanding capacity and adopting technology to improve patient care and operational efficiency. Now turning to our performance, for Q2, Gurgaon Hospital reported its highest ever EBITDA at 23.8%. Our consolidated revenue from operations for Q2 FY27 was INR 311 crores, representing year-on-year growth of 13.2%. Growth was supported by demand across key specialties including cardiac sciences, oncology, neurosciences, orthopaedics and other complex treatments such as transplants. For the first half of FY27, consolidated revenue from operations was INR 598.4 crores, up 13% year-on-year. The performance reflected continued activity at our Gurugram hospital, and the very early contribution from Artemis Shanti Hospital in Raipur, which commenced operations in July 2026. Our consolidated EBITDA for Q2 FY27 was INR 62.89 crores with a margin of 20.2%. While adjusted operational EBITDA for Q2 FY27 was INR 71.5 crores with a margin of 23.3%. Profit after tax for the quarter was INR 31 crore, representing a year-on-year growth of 3.7%. Page 2 of 13 Artemis Medicare Services Limited November 02, 2026 For H1 FY27, consolidated EBITDA was INR 124.7 crores with a margin of 20.8%, while adjusted operational EBITDA for H1 FY27 was INR 133.32 crores with a margin of 22.4%. Profit after tax was INR 62.5 crores with a year-on-year growth of 22.2%. Our focus remains on better utilization of clinical capacity, managing operational costs, and improving the contribution from specialized procedure. Our international patient business remains an important part of Artemis. We serve from Middle East, Africa, CIS, SAC, Canada, Nordic countries and other markets. The spread of our international patient base across more than 150 countries help us avoid dependency on any single region. We remain focused on strengthening referral relationships and developing new source international markets while maintaining our focus on clinical outcomes and patient experience. International patients contributed approximately 30% of the revenue during this quarter. A key development in our expansion plan is Artemis Shanti Hospital in Raipur, our 300-bed multi- specialty tertiary care hospital which began operations in July 2026. The hospital extends our presence in central India, which gives us a new platform to serve patients in this region. As the hospital builds occupancy and more specialties become operational, we are confident about its contribution to increase over time. In the first quarter itself, we have got a feeling of a great response from Central India for Artemis Shanti Hospital. We are also progressing with the next phase of expansion at our Gurugram campus. Tower 4 is planned to add 250 beds within the campus, supported by additional floor area and the benefit available through our Platinum Green Building certification. The project is intended to increase capacity within our existing campus, taking our bed numbers from 700 to 900 plus approximately. We will continue to share updates as the project progresses. Our plans for South Delhi are another important part of our growth strategy. The proposed 650 plus bed tertiary and quaternary care in Lajpat Nagar is expected to strengthen our presence in Delhi, NCR market. The project is being developed under a long-term operation and management contract with the VIMHANS Trust and expected to commence operation in Q4 of FY29-FY30. Along with Raipur and the Gurugram expansion, this facility supports our plan to increase our operational capacity to around 2,000 beds over the next 3 to 5 years. Clinical quality remains central to our strategy. We are developing our centers of excellence across more than 40 specialties, developing further focus on oncology, cardiac sciences, organ transplantation, robotic surgeries, critical care, heart and lung transplantation, etc. Technology is another area of continuous focus. We are using AI-enabled workflows, digital tools, data analytics to improve patient flow, support clinical decisions, and make better use of hospital resources. Initiatives such as AI-assigned triage are intended to help patients receive timely attention, while our wider digital programs aim to improve coordination between clinical and administrative teams. We will continue to assess and expand these initiatives where they can improve patient experience and operating efficiency. We also remain focused on responsible resource use across our hospital. Our priorities include energy efficiency, waste reduction and environmentally Page 3 of 13 Artemis Medicare Services Limited November 02, 2026 responsible operating practices. These efforts form part of our [Showing first 8,000 characters — download PDF for full document]